Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Overview Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Therapeutics Assessment Assessment by Route of Administration Assessment by Molecule Type Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Companies Involved in Therapeutics Development Aduro BioTech Inc Boehringer Ingelheim GmbH Celldex Therapeutics Inc GlaxoSmithKline Plc Immune Design Corp ImmunoFrontier Inc Sanofi Pasteur SA Scancell Holdings Plc Vault Pharma Inc Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Drug Profiles ADU-623 - Drug Profile Product Description Mechanism Of Action R&D Progress BI-1361849 - Drug Profile Product Description Mechanism Of Action R&D Progress CDX-1401 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target CTAG1B for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress CMB-305 - Drug Profile Product Description Mechanism Of Action R&D Progress CMB-305 + G-100 - Drug Profile Product Description Mechanism Of Action R&D Progress CUE-102 - Drug Profile Product Description Mechanism Of Action R&D Progress CYN-102 - Drug Profile Product Description Mechanism Of Action R&D Progress G-305 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2241658A - Drug Profile Product Description Mechanism Of Action R&D Progress IMF-001 - Drug Profile Product Description Mechanism Of Action R&D Progress IMM-65 - Drug Profile Product Description Mechanism Of Action R&D Progress LV-305 - Drug Profile Product Description Mechanism Of Action R&D Progress SCIB-2 - Drug Profile Product Description Mechanism Of Action R&D Progress SV-283 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target NY-ESO-1, PRAME, MAGE-A3 and WT-1 for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress VCP-2292 - Drug Profile Product Description Mechanism Of Action R&D Progress VPI-111 - Drug Profile Product Description Mechanism Of Action R&D Progress Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Dormant Products Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY ESO 1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A or CTAG1B) - Product Development Milestones Featured News & Press Releases Oct 16, 2017: Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients Sep 08, 2017: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response Aug 30, 2017: Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress Jun 26, 2017: Scancell Holdings Announces SCIB-2 Patent Granted in Europe Jun 05, 2017: Immune Design Updates Positive Data from Lead Cancer Immunotherapy Program CMB305 at ASCO Annual Meeting Jun 01, 2017: Immune responses from early study of novel sarcoma vaccine May 17, 2017: New Clinical and Biomarker Data Validate Immune Design's CMB305 Program Dec 05, 2016: Celldex Presents Data on CDX-1401 at the American Society of Hematology Annual Meeting Oct 10, 2016: Scancell preparing SCIB2 for clinical study in lung cancer Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016 Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Products under Development by Companies, H1 2018 (Contd..3), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by Aduro BioTech Inc, H1 2018 Pipeline by Boehringer Ingelheim GmbH, H1 2018 Pipeline by Celldex Therapeutics Inc, H1 2018 Pipeline by GlaxoSmithKline Plc, H1 2018 Pipeline by Immune Design Corp, H1 2018 Pipeline by ImmunoFrontier Inc, H1 2018 Pipeline by Sanofi Pasteur SA, H1 2018 Pipeline by Scancell Holdings Plc, H1 2018 Pipeline by Vault Pharma Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Dormant Products, H1 2018 (Contd..2), H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

Aduro BioTech Inc Boehringer Ingelheim GmbH Celldex Therapeutics Inc GlaxoSmithKline Plc Immune Design Corp ImmunoFrontier Inc Sanofi Pasteur SA Scancell Holdings Plc Vault Pharma Inc